Maximize your ROI with Real-World Evidence (RWE)

April 26, 2016
Many Pharmaceutical companies need to generate efficiencies in developing and commercializing products. PAREXEL Access has both the ability to maximize profitability on marketed products during the drug’s patent but also rapidly penetrate markets with new products using Real-World Evidence. Joshua Schultz, Corporate VP and Head of PAREXEL Access, explains how PAREXEL Access can help clients plan at a portfolio level providing greater strategic advantages and the ability to identify greater cost-efficiency for evidence generation. Through our Real-World Evidence Ecosystem, we drive average cost savings of around 20% by combining multiple late stage studies. PAREXEL Access has an integrated market access consultancy, supporting more than 200 HTA submissions, in 12 countries, and over 200 economic modeling programs
Previous Video
Drive Cost-Efficiencies with Real-World Evidence (RWE)
Drive Cost-Efficiencies with Real-World Evidence (RWE)

Pharmaceutical Companies today need post-approval data to demonstrate product value in an environment where...

Next Video
David Godwin   One PAREXEL
David Godwin One PAREXEL